ESMO 2023
Insightful updates from ESMO 2023, bringing the latest breakthroughs and trends in oncology from global pharma leaders. Stay informed with Pharmtales.
![Amulet, Watchman tie in heart occluder study | Pharmtales](https://pharmtales.com/wp-content/uploads/2023/10/Abbotts-Amulet-Bostons-Watchman-equal-in-heart-occluder-trial.jpg)
Abbottâs Amulet, Bostonâs Watchman equal in heart occluder trial
The study, presented as a late-breaking feature at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, assessed the safety and ...
![Daiichi, AZ grow ADC portfolios post Enhertu | Pharmtales](https://pharmtales.com/wp-content/uploads/2023/10/Daiichi-and-AstraZeneca-expand-ADC-pipelines-after-Enhertu-triumph.jpg)
Daiichi and AstraZeneca expand ADC pipelines after Enhertu triumph
At the European Society for Medical Oncology (ESMO) Congress, Daiichi Sankyo made a significant impact by striking a $4 billion ...
![Cancer vaccine challenges for Moderna, BioNTech](https://pharmtales.com/wp-content/uploads/2023/10/Moderna-BioNTech-face-hurdles-in-cancer-vaccine-production-after-COVID-success.jpg)
Moderna, BioNTech face hurdles in cancer vaccine production after COVID success
Moderna and BioNTech, both navigating their post-COVID future while reimagining cancer treatments, have encountered manufacturing hurdles along their respective journeys. ...
![Keytruda: Merckâs cancer drug shines and falters at ESMO](https://pharmtales.com/wp-content/uploads/2023/10/Keytruda_-Mercks-breakthrough-cancer-drug-with-mixed-results-at-ESMO.jpg)
Keytruda: Merckâs breakthrough cancer drug with mixed results at ESMO
Merck & Co. made significant strides at this year’s European Society for Medical Oncology (ESMO) congress, presenting a series of ...
![BioNTechâs CAR-T/CARVac Combo: Potent but Toxic (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/BioNTechs-CAR-T_CARVac-Combo-Shows-High-Response-Rates-in-Solid-Tumors-But-Also-Higher-Toxicity-ESMO-2023.jpg)
BioNTechâs CAR-T/CARVac Combo Shows High Response Rates in Solid Tumors, But Also Higher Toxicity (ESMO 2023)
ESMO 2023: LBA35 BioNTech’s innovative manufacturing process for CAR-T therapy, BNT211, has shown promising results in treating solid tumors. While ...
![Dato-DXdâs Mixed Results in Lung Cancer Trial (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Dato-DXd-Shows-Efficacy-in-Lung-Cancer-But-Safety-Issues-Remain-ESMO-2023.jpg)
Dato-DXd Shows Efficacy in Lung Cancer, But Safety Issues Remain (ESMO 2023)
ESMO 2023: LBA12 During the Presidential Symposium at the ESMO Congress 2023 in Madrid, a study revealed that datopotamab deruxtecan, ...
![Pluvictoâs Hot-and-Cold Results in Prostate Cancer (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Pluvicto-Improves-Survival-in-Earlier-Prostate-Cancer-But-Faces-Regulatory-Hurdles-ESMO-2023-1.jpg)
Pluvicto Improves Survival in Earlier Prostate Cancer, But Faces Regulatory Hurdles (ESMO 2023)
ESMO 2023: LBA13 Novartis is eagerly advancing its radiotherapy drug, Pluvicto, with aspirations of its potential in earlier prostate cancer ...
![Ambrxâs ARX517 Impresses in Prostate Cancer Trial (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Ambrxs-ARX517-Shows-Promising-Efficacy-and-Safety-in-Advanced-Prostate-Cancer-ESMO-2023.jpg)
Ambrxâs ARX517 Shows Promising Efficacy and Safety in Advanced Prostate Cancer (ESMO 2023)
ESMO 2023: 1804P As of the data cutoff date in September 2023, the results from the study show that increasing ...
![Merusâ Zeno Improves Outcomes in NRG1+ Cancers (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Merus-Zeno-Shows-Higher-Response-Rates-in-NRG1-Pancreatic-and-Lung-Cancers-ESMO-2023.jpg)
Merusâ Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)
ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...
![Imfinzi-Lynparza Beats Chemo in Endometrial Cancer (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Imfinzi-and-Lynparza-Combo-Improves-Survival-in-Endometrial-Cancer-Trial-ESMO-2023.jpg)
Imfinzi and Lynparza Combo Improves Survival in Endometrial Cancer Trial (ESMO 2023)
ESMO 2023: LBA41 AstraZeneca is exploring a potentially powerful approach in the fight against endometrial cancer, suggesting that combining their ...
![Cabometyx Halts Trial Early in Neuroendocrine Tumors (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Cabometyx-Shows-Dramatic-Benefits-in-Advanced-Neuroendocrine-Tumors-ESMO-2023.jpg)
Cabometyx Shows Dramatic Benefits in Advanced Neuroendocrine Tumors (ESMO 2023)
ESMO 2023: LBA53 Exelixis made headlines last month when its Cabometyx exceeded expectations in the treatment of neuroendocrine tumors (NETs), ...
![Padcev-Keytruda Beats Chemo in Bladder Cancer (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Padcev-Keytruda-Combo-Doubles-Survival-in-First-Line-Bladder-Cancer-Trial-ESMO-2023.jpg)
Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)
ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...
![Opdivo vs Chemo vs Keytruda-Padcev in Bladder Cancer (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Opdivo-Beats-Chemo-in-First-Line-Bladder-Cancer-But-Keytruda-Padcev-Combo-Looms-Large-ESMO-2023.jpg)
Opdivo Beats Chemo in First-Line Bladder Cancer, But Keytruda-Padcev Combo Looms Large (ESMO 2023)
ESMO 2023: LBA7 Bladder cancer has presented a unique challenge for immunotherapies, with Bristol Myers Squibb’s Opdivo making strides, but ...
![Lumakras Boosts PFS in KRAS G12C-Mutated CRC (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Lumakras-Vectibix-combo-outperforms-standard-therapy-in-KRAS-G12C-mutated-colorectal-cancer-ESMO-2023.jpg)
Lumakras-Vectibix combo outperforms standard therapy in KRAS G12C-mutated colorectal cancer (ESMO 2023)
ESMO 2023: LBA10 Nevertheless, a shadow has been cast over the KRAS inhibitor due to recent criticisms by FDA advisors. ...
![Retevmo Beats Keytruda + Chemo in RET+ NSCLC](https://pharmtales.com/wp-content/uploads/2023/10/Lilly-Unveils-Exciting-Phase-III-Showdown_-Retevmo-vs.-Keytruda-Chemotherapy-in-RET-Fusion-Positive-NSCLC.jpg)
Lilly Unveils Exciting Phase III Showdown: Retevmo vs. Keytruda & Chemotherapy in RET Fusion-Positive NSCLC
ESMO 2023: LBA4 RET fusion is found in about 1-2% of patients with non-small cell lung cancer. Retevmo, a highly ...
![Alecensa Lowers Recurrence and Death in ALK+ NSCLC](https://pharmtales.com/wp-content/uploads/2023/10/Phase-III-ALINA-study-shows-Alecensas-superior-disease-free-survival-benefit-in-early-stage-lung-cancer-patients.jpg)
Phase III ALINA study shows Alecensaâs superior disease-free survival benefit in early-stage lung cancer patients
ESMO 2023: LBA2 About 4-5% of NSCLC cases are identified with ALK rearrangements. In 2015, Alecensa (alectinib) received accelerated approval ...
![Garsorasib + Cetuximab Active in KRAS G12C-Mutated CRC](https://pharmtales.com/wp-content/uploads/2023/10/A-novel-combination-therapy-of-garsorasib-and-cetuximab-for-KRAS-G12C-mutated-colorectal-cancer-patients.jpg)
A novel combination therapy of garsorasib and cetuximab for KRAS G12C mutated colorectal cancer patients
Dâ1553 is a small-molecule inhibitor designed to selectively target KRAS G12C and is currently undergoing Phase II clinical trials. It ...
![Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial](https://pharmtales.com/wp-content/uploads/2023/10/Combination-of-Osimertinib-and-Chemotherapy-Enhances-Brain-Control-in-Advanced-EGFR-Mutated-Lung-Cancer-Results-from-FLAURA2-Trial.jpg)
Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial
ESMO: LBA68 EGFR mutations are found in 10%-15% of non-small cell lung cancer (NSCLC) cases among European and Caucasian populations. ...
![Imfinzi + Chemo Improves pCR in Gastric and GEJ Cancers (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/IMFINZI-Chemo-Improves-pCR-in-Gastric-and-GEJ-Cancers.jpg)
Positive Interim Results from Global Phase III MATTERHORN Study: Imfinzi plus FLOT Demonstrates Clinically Meaningful Improvement in Key Secondary Endpoint (ESMO 2023)
ESMO 2023: LBA73 The results of a MATTERHORN trial was presented in ESMO 2023. The trial tested the effect of ...
![Tarlatamab Improves Survival in Advanced SCLC (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Phase-II-DeLLphi-301-Study-Reveals-Impressive-Antitumor-Activity-of-Amgens-First-in-Class-Bispecific-Antibody-Tarlatamab.jpg)
Phase II DeLLphi-301 Study Reveals Impressive Antitumor Activity of Amgen’s First-in-Class Bispecific Antibody Tarlatamab (ESMO 2023)
ESMO 2023: LBA92 Most SCLC patients are diagnosed with cancer that has already spread beyond the lungs, and their average ...
![Krazati + Keytruda Slows Down KRASG12C-Mutated NSCLC (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Krazati-Keytruda-Slows-Down-KRASG12C-Mutated-NSCLC.jpg)
Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-NaĂŻve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)
ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...
![Keytruda + Chemo Boosts Survival in Resectable NSCLC (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/KEYNOTE-671-Trial_-Keytruda-Sets-New-Standards-in-the-Perioperative-Treatment-Landscape.jpg)
KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)
ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merckâs Keytruda is ...
![ESMO 2023: Keytruda + Chemo Boosts pCR in ER+/HER2â Breast Cancer](https://pharmtales.com/wp-content/uploads/2023/10/Keytrudas-Success-in-KEYNOTE-756-Trial-Ushers-in-a-New-Era-for-Early-Stage-High-Risk-ER_HER2â-Breast-Cancer-Treatment.jpg)
Keytruda’s Success in KEYNOTE-756 Trial Ushers in a New Era for Early-Stage High-Risk ER+/HER2â Breast Cancer Treatment (ESMO 2023)
ESMO 2023: LBA21 Keytruda (pembrolizumab) is a highly specific, human-made antibody that targets the PD-1 pathway and prevents cancer cells ...
![ESMO 2023](https://pharmtales.com/wp-content/uploads/2023/10/Rybrevant-Redefines-First-Line-Care-for-Patients-with-EGFR-Exon-20-Insertion-Mutation.jpg)
Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)
ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...
![ESMO 2023: Opdivo + Chemo Boosts Survival in Resectable NSCLC](https://pharmtales.com/wp-content/uploads/2023/10/ESMO-2023-Bristol-Myers-Squibbs-Opdivo-Plus-Chemotherapy-Improves-Survival-in-Resectable-NSCLC-CheckMate-816-Trial.jpg)
ESMO 2023: Bristol Myers Squibbâs Opdivo Plus Chemotherapy Improves Survival in Resectable NSCLC: CheckMate -816 Trial
ESMO 2023: Abstract ID 1261O Treating early-stage NSCLC presents numerous obstacles, given the restricted therapeutic alternatives available. In this landscape, ...
![Conference, ESMO 2023, Keytruda, Breast Cancer, LBA18, KEYNOTE-522](https://pharmtales.com/wp-content/uploads/2023/10/How-Keytruda-Improved-Survival-Outcomes-for-Early-Stage-TNBC-Patients-KEYNOTE-522-Trial.jpg)
How Keytruda Improved Survival Outcomes for Early-Stage TNBC Patients: KEYNOTE-522 Trial
ESMO 2023: LBA18 Underpinning this approval is the seminal KEYNOTE-522 trial, a Phase III study that diverges from pre-2021 tactics ...
![ESMO 2023: Jemperli outperforms Keytruda in lung cancer trial](https://pharmtales.com/wp-content/uploads/2023/10/ESMO-2023_-GSKs-Jemperli-beats-Mercks-Keytruda-in-lung-cancer-survival-trial.jpg)
ESMO 2023: GSKâs Jemperli beats Merckâs Keytruda in lung cancer survival trial
In a groundbreaking clinical trial, GSK has achieved remarkable patient survival results with its PD-1 inhibitor, Jemperli, when compared to ...